

## Guest editorial:

# HIGHLIGHT REPORT: GENERAL DETERMINANTS OF STEATOSIS

Wiebke Albrecht

IfADo – Leibniz Research Centre for Working Environment and Human Factors at  
TU Dortmund, Ardeystr. 67, D-44139 Dortmund, Germany,  
e-mail: [albrecht@ifado.de](mailto:albrecht@ifado.de)

<http://dx.doi.org/10.17179/excli2018-2011>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License  
(<http://creativecommons.org/licenses/by/4.0/>).

Recently Christian Hudert and colleagues from the Charité in Berlin published a study about genetic determinants in pediatric non-alcoholic liver disease (Hudert et al., 2018). Non-alcoholic fatty liver disease (NAFLD), the most frequent chronic liver disease in children, is known to be strongly influenced by genetic factors (Nobili et al., 2016; Schwimmer et al., 2006; Makkonen et al., 2009; Anstee et al., 2016). However, genetic determinants of a portal/zone-1 pattern of steatosis in children are not yet known. This would be important, because a portal/zone-1 pattern of steatosis leads to an increased risk of disease progression to fibrosis (Africa et al., 2018; Mann et al., 2016). To address this question, the authors established the Berlin adolescence NAFLD cohort (BaNA) and studied a set of single nucleotide polymorphisms. Interestingly, a variant of the retinyl-palmitate lipase PNPLA3 (rs738409) was associated with a periportal pattern of steatosis and also with an increased risk of progression to fibrosis (Hudert et al., 2018). Therefore, obese children with the PNPLA3 variant may be candidates for a more intensive clinical follow-up and intervention.

Due to the current increase in the incidence of liver diseases a better understanding of their pathophysiology is of major importance (Jansen et al., 2017; Vartak et al., 2016; Hammad et al., 2014; Hassan, 2016;

Stöber, 2016; Bolt, 2017; Ekhlesi et al., 2017). For this purpose systems modeling as well as the analysis of expression patterns in relation to a phenotype represent frequently applied tools (Godoy et al., 2016; Crespo Yanguas et al., 2016; Jain et al., 2016; Saleem et al., 2016; Schenk et al., 2017; Thiel et al., 2015). The newly established BaNA cohort of adolescent NAFLD with its careful phenotyping and availability of proteome data is an important milestone for a better understanding of disease progression in steatosis.

## REFERENCES

- Africa JA, Behling CA, Brunt EM, Zhang N, Luo Y, Wells A, et al. In children with nonalcoholic fatty liver disease, Zone 1 steatosis is associated with advanced fibrosis. *Clin Gastroenterol Hepatol.* 2018;16:438-46.e1.
- Anstee QM, Seth D, Day CP. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. *Gastroenterology.* 2016;150:1728-44.e7.
- Bolt HM. Highlight report: The pseudolobule in liver fibrosis. *EXCLI J.* 2017;16:1321-2.
- Crespo Yanguas S, Willebrords J, Maes M, da Silva TC, Veloso Alves Pereira I, Cogliati B, et al. Connexins and pannexins in liver damage. *EXCLI J.* 2016;15:177-86.

- Ekhlas G, Zarrati M, Agah S, Hosseini AF, Hosseini S, Shidfar S, et al. Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease. *EXCLI J.* 2017;16:278-90.
- Godoy P, Widera A, Schmidt-Heck W, Campos G, Meyer C, Cadenas C, et al. Gene network activity in cultivated primary hepatocytes is highly similar to diseased mammalian liver tissue. *Arch Toxicol.* 2016;90:2513-29.
- Hammad S, Hoehme S, Friebel A, von Recklinghausen I, Othman A, Begher-Tibbe B, et al. Protocols for staining of bile canalicular and sinusoidal networks of human, mouse and pig livers, three-dimensional reconstruction and quantification of tissue microarchitecture by image processing and analysis. *Arch Toxicol.* 2014;88:1161-83.
- Hassan R. Possibilities and limitations of intravital imaging. *EXCLI J.* 2016;15:872-4.
- Hudert CA, Selinski S, Rudolph B, Bläker H, Loddenkemper C, Thielhorn R, et al. Genetic determinants of steatosis and fibrosis progression in pediatric non-alcoholic fatty liver disease. *Liver Int.* 2018 Nov 16. doi: 10.1111/liv.14006. [Epub ahead of print].
- Jain PG, Surana SJ. Isolation, characterization and hypolipidemic activity of ferulic acid in high-fat-diet-induced hyperlipidemia in laboratory rats. *EXCLI J.* 2016;15:599-613.
- Jansen PL, Ghallab A, Vartak N, Reif R, Schaap FG, Hampe J, et al. The ascending pathophysiology of cholestatic liver disease. *Hepatology.* 2017;65:722-38.
- Makkonen J, Pietiläinen KH, Rissanen A, Kaprio J, Yki-Järvinen H. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. *J Hepatol.* 2009;50:1035-42.
- Mann JP, De Vito R, Mosca A, Alisi A, Armstrong MJ, Raponi M, et al. Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease. *Hepatology.* 2016;63:745-53.
- Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. *Gastroenterology.* 2016;150:1798-810.
- Saleem A, Akhtar MF, Mushtaq MF, Saleem M, Muhammad ST, Akhtar B, et al. Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs. *EXCLI J.* 2016;15:578-88.
- Schenk A, Ghallab A, Hofmann U, Hassan R, Schwarz M, Schuppert A, et al. Physiologically-based modeling in mice suggests an aggravated loss of clearance capacity after toxic liver damage. *Sci Rep.* 2017;7(1):6224.
- Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics.* 2006;118:1388-93.
- Stöber R. Pathophysiology of cholestatic liver disease and its relevance for in vitro tests of hepatotoxicity. *EXCLI J.* 2016;15:870-1.
- Thiel C, Schneckener S, Krauss M, Ghallab A, Hofmann U, Kanacher T, et al. A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation. *J Pharm Sci.* 2015;104:191-206.
- Vartak N, Damle-Vartak A, Richter B, Dirsch O, Dahmen U, Hammad S, et al. Cholestasis-induced adaptive remodeling of interlobular bile ducts. *Hepatology.* 2016;63:951-64.